La Jolla Pharmaceutical Company (LJPC): Price and Financial Metrics


La Jolla Pharmaceutical Company (LJPC): $3.77

-0.08 (-2.08%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add LJPC to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

LJPC POWR Grades


  • Quality is the dimension where LJPC ranks best; there it ranks ahead of 98.32% of US stocks.
  • LJPC's strongest trending metric is Stability; it's been moving up over the last 179 days.
  • LJPC ranks lowest in Momentum; there it ranks in the 12th percentile.

LJPC Stock Summary

  • La Jolla Pharmaceutical Co's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 3.95% of US listed stocks.
  • LJPC's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 4.61% of US stocks.
  • With a year-over-year growth in debt of 393.1%, La Jolla Pharmaceutical Co's debt growth rate surpasses 96.69% of about US stocks.
  • Stocks that are quantitatively similar to LJPC, based on their financial statements, market capitalization, and price volatility, are PUBM, OMCL, UPST, EQX, and HEAR.
  • Visit LJPC's SEC page to see the company's official filings. To visit the company's web site, go to lajollapharmaceutical.com.

LJPC Valuation Summary

  • LJPC's price/sales ratio is 1.6; this is 85.9% lower than that of the median Healthcare stock.
  • LJPC's price/sales ratio has moved NA NA over the prior 115 months.
  • LJPC's price/earnings ratio has moved up 39.7 over the prior 115 months.

Below are key valuation metrics over time for LJPC.

Stock Date P/S P/B P/E EV/EBIT
LJPC 2021-08-31 1.6 -1.7 39.7 5.2
LJPC 2021-08-30 1.7 -1.8 41.1 5.6
LJPC 2021-08-27 1.7 -1.8 41.2 5.6
LJPC 2021-08-26 1.7 -1.8 40.6 5.4
LJPC 2021-08-25 1.6 -1.7 39.1 5.1
LJPC 2021-08-24 1.6 -1.6 38.0 4.9

LJPC Growth Metrics

    The 2 year net cashflow from operations growth rate now stands at 40.59%.
  • Its 4 year net income to common stockholders growth rate is now at -88.95%.
  • The 4 year net cashflow from operations growth rate now stands at -97.43%.
Over the past 34 months, LJPC's revenue has gone up $62,078,000.

The table below shows LJPC's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 75.72 28.244 19.66
2021-09-30 74.461 17.798 12.413
2021-06-30 70.219 7.269 2.913
2021-03-31 59.965 -8.213 -16.412
2020-12-31 33.419 -37.64 -39.421
2020-09-30 29.718 -47.49 -61.176

LJPC's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • LJPC has a Quality Grade of B, ranking ahead of 86.96% of graded US stocks.
  • LJPC's asset turnover comes in at 0.82 -- ranking 32nd of 680 Pharmaceutical Products stocks.
  • BTX, ITCI, and LFVN are the stocks whose asset turnover ratios are most correlated with LJPC.

The table below shows LJPC's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.820 0.789 3.880
2021-03-31 0.685 0.776 -0.445
2020-12-31 0.353 0.766 -1.176
2020-09-30 0.271 0.838 -1.457
2020-06-30 0.208 0.891 -1.450
2020-03-31 0.184 0.901 -1.704

LJPC Price Target

For more insight on analysts targets of LJPC, see our LJPC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $4.50 Average Broker Recommendation 2 (Hold)

LJPC Stock Price Chart Interactive Chart >

Price chart for LJPC

LJPC Price/Volume Stats

Current price $3.77 52-week high $5.69
Prev. close $3.85 52-week low $3.44
Day low $3.75 Volume 56,300
Day high $3.91 Avg. volume 74,146
50-day MA $4.12 Dividend yield N/A
200-day MA $4.19 Market Cap 96.35M

La Jolla Pharmaceutical Company (LJPC) Company Bio


La Jolla Pharmaceutical is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for the treatment of serious bacterial infections and rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy. The company was founded in 1989 and is based in San Diego, California.


LJPC Latest News Stream


Event/Time News Detail
Loading, please wait...

LJPC Latest Social Stream


Loading social stream, please wait...

View Full LJPC Social Stream

Latest LJPC News From Around the Web

Below are the latest news stories about La Jolla Pharmaceutical Co that investors may wish to consider to help them evaluate LJPC as an investment opportunity.

What Kind Of Shareholders Own La Jolla Pharmaceutical Company (NASDAQ:LJPC)?

Every investor in La Jolla Pharmaceutical Company ( NASDAQ:LJPC ) should be aware of the most powerful shareholder...

Yahoo | January 24, 2022

HealthInvest Partners AB Buys McKesson Corp, Cardinal Health Inc, AmerisourceBergen Corp, Sells ...

Stockholm, V7, based Investment company HealthInvest Partners AB (Current Portfolio) buys McKesson Corp, Cardinal Health Inc, AmerisourceBergen Corp, Bristol-Myers Squibb Co, AbbVie Inc, sells Supernus Pharmaceuticals Inc, Accuray Inc, Aldeyra Therapeutics Inc, Rigel Pharmaceuticals Inc, Evolus Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, HealthInvest Partners AB.

Yahoo | January 18, 2022

La Jolla Pharmaceutical (NASDAQ:LJPC) Upgraded by Zacks Investment Research to Buy

Zacks Investment Research upgraded shares of La Jolla Pharmaceutical (NASDAQ:LJPC) from a hold rating to a buy rating in a research note issued to investors on Wednesday morning, Zacks.com reports. They currently have $5.00 price objective on the biopharmaceutical companys stock. According to Zacks, LA JOLLA PHARMACEUTICAL CO. is engaged in the research and development []

Dakota Financial News | December 18, 2021

La Jolla Pharmaceutical (NASDAQ:LJPC) Downgraded by Zacks Investment Research

La Jolla Pharmaceutical (NASDAQ:LJPC) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Tuesday, Zacks.com reports. According to Zacks, “LA JOLLA PHARMACEUTICAL CO. is engaged in the research and development of therapeutic products for the treatment of autoimmune and inflammatory diseases. “ NASDAQ:LJPC opened […]

Dakota Financial News | December 14, 2021

La Jolla Pharmaceutical Company (NASDAQ: LJPC) Rise 5.08%, Now What? Dont Panic

La Jolla Pharmaceutical Company (NASDAQ:LJPC) price on Friday, December 10, rose 5.08% above its previous days close as an upside momentum from buyers pushed the stocks value to $4.55. A look at the stocks price movement, the close in the last trading session was $4.33. The beta value (5-Year monthly) was 2.36 while the PE La Jolla Pharmaceutical Company (NASDAQ: LJPC) Rise 5.08%, Now What? Dont Panic Read More »

Stocks Register | December 11, 2021

Read More 'LJPC' Stories Here

LJPC Price Returns

1-mo -3.58%
3-mo -4.80%
6-mo -19.79%
1-year -16.22%
3-year -29.66%
5-year -87.01%
YTD -18.92%
2021 19.85%
2020 -1.27%
2019 -58.32%
2018 -70.70%
2017 83.57%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.2688 seconds.